Last reviewed · How we verify
Dexamethasone IV for PO
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.
Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Acute inflammation and immune suppression (various conditions), Cerebral edema, Adrenocortical insufficiency.
At a glance
| Generic name | Dexamethasone IV for PO |
|---|---|
| Also known as | Dexamethasone injection |
| Sponsor | Vanderbilt University Medical Center |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Inflammation, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene expression. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory responses. The IV formulation allows rapid systemic delivery for acute inflammatory or immunosuppressive needs, with conversion to oral dosing as clinically appropriate.
Approved indications
- Acute inflammation and immune suppression (various conditions)
- Cerebral edema
- Adrenocortical insufficiency
- Severe allergic reactions
- Autoimmune and rheumatologic disorders
Common side effects
- Hyperglycemia
- Insomnia
- Mood changes (euphoria, anxiety, depression)
- Hypertension
- Immunosuppression / increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
- Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (PHASE2)
- Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone IV for PO CI brief — competitive landscape report
- Dexamethasone IV for PO updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI